Harnessing Immune Response in Acute Myeloid Leukemia

Despite the results achieved with the evolution of conventional chemotherapy and the inclusion of targeted therapies in the treatment of acute myeloid leukemia (AML), survival is still not satisfying, in particular in the setting of relapsed/refractory (R/R) disease or elderly/unfit patients. Among the most innovative therapeutic options, cellular therapy has shown great results in different hematological malignancies such as acute lymphoblastic leukemia and lymphomas, with several products already approved for clinical use. However, despite the great interest in also expanding the application of these new treatments to R/R AML, no product has been approved yet for clinical application. Furthermore, cellular therapy could indeed represent a powerful tool and an appealing alternative to allogeneic hematopoietic stem cell transplantation for ineligible patients. In this review, we aim to provide an overview of the most recent clinical research exploring the effectiveness of cellular therapy in AML, moving from consolidated approaches such as post- transplant donor’s lymphocytes infusion, to modern adoptive immunotherapies such as alloreactive NK cell infusions, engineered T and NK cells (CAR-T, CAR-NK) and novel platforms of T and NK cells engaging (i.e., BiTEs, DARTs and ANKETTM).

[1]  G. Gaidano,et al.  Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy , 2023, Haematologica.

[2]  C. Nicolazzi,et al.  Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123 , 2023, Nature Biotechnology.

[3]  Xiang Li,et al.  First‐in‐human study of JNJ‐63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia , 2022, Clinical and translational science.

[4]  J. Mascarenhas,et al.  The Latest Breakthroughs in Immunotherapy for Acute Myeloid Leukemia, with a Special Focus on NKG2D Ligands , 2022, International journal of molecular sciences.

[5]  K. Wucherpfennig,et al.  Designing Cancer Immunotherapies That Engage T Cells and NK Cells. , 2022, Annual review of immunology.

[6]  M. Jongen‐Lavrencic,et al.  An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS) , 2022, Blood.

[7]  D. Steiner,et al.  MP0533: A Multispecific Darpin CD3 Engager Targeting CD33, CD123, and CD70 for the Treatment of AML and MDS Designed to Selectively Target Leukemic Stem Cells , 2022, Blood.

[8]  Jiaxing Wang,et al.  First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia , 2022, Journal of Hematology & Oncology.

[9]  B. Ebert,et al.  Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel. , 2022, Blood.

[10]  R. Schubert,et al.  Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia , 2022, Blood Cancer Journal.

[11]  Zhong-chao Han,et al.  CAR-NK cells for cancer immunotherapy: from bench to bedside , 2022, Biomarker Research.

[12]  Justin C. Boucher,et al.  Emerging CAR T Cell Strategies for the Treatment of AML , 2022, Cancers.

[13]  C. Thiede,et al.  Analysis of Subset Chimerism for MRD-Detection and Pre-Emptive Treatment in AML , 2022, Frontiers in Oncology.

[14]  D. Olive,et al.  Safety of Anti-NKG2A Blocking Antibody Monalizumab As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I Study , 2021, Blood.

[15]  D. Vallera,et al.  444 GTB-3550 tri-specific killer engager TriKE™ drives NK cells expansion and cytotoxicity in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients , 2021, Journal for ImmunoTherapy of Cancer.

[16]  A. Curti,et al.  Emerging Bone Marrow Microenvironment-Driven Mechanisms of Drug Resistance in Acute Myeloid Leukemia: Tangle or Chance? , 2021, Cancers.

[17]  F. Baron,et al.  Sequential administration of low dose 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): a prospective study from the Belgian Hematology Society (BHS) , 2021, Bone Marrow Transplantation.

[18]  F. Uckun,et al.  A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome , 2021, Cancers.

[19]  Walid Kamal Abdelbasset,et al.  CAR-NK Cell: A New Paradigm in Tumor Immunotherapy , 2021, Frontiers in Oncology.

[20]  N. Daver,et al.  T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments , 2021, Leukemia.

[21]  N. Daver,et al.  Editorial: The Biological Landscape of Immunotherapy in AML , 2021, Frontiers in Oncology.

[22]  M. Konopleva,et al.  Acute myeloid leukemia: current progress and future directions , 2021, Blood Cancer Journal.

[23]  M. Maus,et al.  Recent advances and discoveries in the mechanisms and functions of CAR T cells , 2021, Nature Reviews Cancer.

[24]  K. Rezvani,et al.  CAR‐NK cells: the next wave of cellular therapy for cancer , 2021, Clinical & translational immunology.

[25]  Hong-Gang Wang,et al.  Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia , 2020, Journal of Hematology & Oncology.

[26]  F. Ravandi,et al.  Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study , 2020, Blood.

[27]  S. Rutella,et al.  Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia , 2020 .

[28]  J. Khoury,et al.  CD123 as a Biomarker in Hematolymphoid Malignancies: Principles of Detection and Targeted Therapies , 2020, Cancers.

[29]  P. Paschka,et al.  Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed/refractory acute myeloid leukemia (R/R AML). , 2020 .

[30]  I. Gojo,et al.  Immune escape and immunotherapy of acute myeloid leukemia. , 2020, The Journal of clinical investigation.

[31]  M. Xie,et al.  Tumor-Derived Soluble MICA Obstructs the NKG2D Pathway to Restrain NK Cytotoxicity , 2020, Aging and disease.

[32]  C. Genova,et al.  Harnessing NK Cells for Cancer Treatment , 2019, Front. Immunol..

[33]  P. Vyas,et al.  The Graft-Versus-Leukemia Effect in AML , 2019, Front. Oncol..

[34]  K. Odunsi,et al.  Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients , 2019, Blood.

[35]  R. Varadhan,et al.  Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients , 2019, Blood.

[36]  F. Ravandi,et al.  Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) , 2019, Blood.

[37]  L. Rönnstrand,et al.  FMS-like Tyrosine Kinase 3/FLT3: From Basic Science to Clinical Implications. , 2019, Physiological reviews.

[38]  Janice M Reichert,et al.  Bispecific antibodies: a mechanistic review of the pipeline , 2019, Nature Reviews Drug Discovery.

[39]  S. Parmar,et al.  Targeting CLL-1 for acute myeloid leukemia therapy , 2019, Journal of Hematology & Oncology.

[40]  Clara Di Vito,et al.  NK cells to cure cancer. , 2019, Seminars in immunology.

[41]  P. Dreger,et al.  Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML) , 2019, Journal of clinical medicine.

[42]  O. Lantz,et al.  Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells , 2018, Cell.

[43]  P. Sharma,et al.  The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia , 2018, Cancer.

[44]  J. Esteve,et al.  Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia – a matched pair analysis by the Acute Leukaemia Working Party of EBMT , 2018, British journal of haematology.

[45]  J. V. van Dongen,et al.  CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping , 2018, Cytometry. Part B, Clinical cytometry.

[46]  P. Sharma,et al.  Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. , 2018, Cancer discovery.

[47]  Yu Wang,et al.  Reversal of T Cell Exhaustion by the First Donor Lymphocyte Infusion Is Associated with the Persistently Effective Antileukemic Responses in Patients with Relapsed AML after Allo-HSCT. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[48]  S. Tasian.  Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled? , 2018, Therapeutic advances in hematology.

[49]  S. Bicciato,et al.  The early expansion of anergic NKG2Apos/CD56dim/CD16neg natural killer represents a therapeutic target in haploidentical hematopoietic stem cell transplantation , 2018, Haematologica.

[50]  Omkar U. Kawalekar,et al.  CAR T cell immunotherapy for human cancer , 2018, Science.

[51]  E. Chiffoleau,et al.  C-Type Lectin-Like Receptors As Emerging Orchestrators of Sterile Inflammation Represent Potential Therapeutic Targets , 2018, Front. Immunol..

[52]  A. Al-Mawali,et al.  CD34+CD38-CD123+ Cells Are Present in Virtually All Acute Myeloid Leukaemia Blasts: A Promising Single Unique Phenotype for Minimal Residual Disease Detection , 2017, Acta Haematologica.

[53]  C. Hourigan,et al.  The Prognostic Significance of Measurable (“Minimal”) Residual Disease in Acute Myeloid Leukemia , 2017, Current Hematologic Malignancy Reports.

[54]  J. Esteve,et al.  Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT , 2016, Bone Marrow Transplantation.

[55]  S. Marnitz,et al.  Checkpoint inhibitors and radiation treatment in Hodgkin’s lymphoma , 2016, Strahlentherapie und Onkologie.

[56]  J. Kochenderfer,et al.  Toxicities of chimeric antigen receptor T cells: recognition and management. , 2016, Blood.

[57]  A. Wolf,et al.  Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications , 2016, Clinical Pharmacokinetics.

[58]  J. Guenot,et al.  Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia , 2016, Clinical Cancer Research.

[59]  A. Tosti,et al.  Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells , 2016, Haematologica.

[60]  L. Ruggeri,et al.  Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients , 2016, Clinical Cancer Research.

[61]  Andreas Plückthun,et al.  Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy. , 2015, Annual review of pharmacology and toxicology.

[62]  Ya-Zhen Qin,et al.  In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification. , 2014, Blood.

[63]  I. Buño,et al.  Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation , 2014, European journal of haematology.

[64]  E. Estey,et al.  Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. , 2014, The Lancet. Oncology.

[65]  D. Pollyea,et al.  Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials , 2014, Haematologica.

[66]  S. Grupp,et al.  Current concepts in the diagnosis and management of cytokine release syndrome. , 2014, Blood.

[67]  He Huang,et al.  Superiority of preemptive donor lymphocyte infusion based on minimal residual disease in acute leukemia patients after allogeneic hematopoietic stem cell transplantation , 2014, Transfusion.

[68]  Catherine J. Wu,et al.  Understanding anti-leukemia responses to donor lymphocyte infusion , 2014, Oncoimmunology.

[69]  N. Hacohen,et al.  Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. , 2014, Blood.

[70]  O. Landt,et al.  The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. , 2013, Blood.

[71]  Bin Zhang,et al.  Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 × 33 Bispecific Killer Cell Engager and ADAM17 Inhibition , 2013, Clinical Cancer Research.

[72]  L. Weiner,et al.  Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production , 2012, Molecular Cancer Therapeutics.

[73]  C. Craddock,et al.  Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[75]  Yan-rong Liu,et al.  Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. , 2012, Blood.

[76]  A. Moretta,et al.  Role of alloreactive KIR2DS1+ NK cells in haploidentical hematopoietic stem cell transplantation , 2011, Journal of leukocyte biology.

[77]  M. Baccarani,et al.  Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. , 2011, Blood.

[78]  C. Rader.  DARTs take aim at BiTEs. , 2011, Blood.

[79]  R. Hills,et al.  Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  F. Locatelli,et al.  Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. , 2011, Blood.

[81]  P. Ljungman,et al.  Leukemia lineage-specific chimerism analysis and molecular monitoring improve outcome of donor lymphocyte infusions. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[82]  C. Pui,et al.  NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  F. Locatelli,et al.  Activating and inhibitory killer immunoglobulin‐like receptors (KIR) in haploidentical haemopoietic stem cell transplantation to cure high‐risk leukaemias , 2009, Clinical and experimental immunology.

[84]  M. Martinetti,et al.  Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. , 2009, Blood.

[85]  H. Kolb.  Graft-versus-leukemia effects of transplantation and donor lymphocytes. , 2008, Blood.

[86]  B. Barlogie,et al.  Infusion of haplo‐identical killer immunoglobulin‐like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation , 2008, British journal of haematology.

[87]  H. Binz,et al.  DARPins: a new generation of protein therapeutics. , 2008, Drug discovery today.

[88]  P. Kufer,et al.  Strictly Target Cell-dependent Activation of T Cells by Bispecific Single-chain Antibody Constructs of the BiTE Class , 2007 .

[89]  M. Gobbi,et al.  Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia. , 2007, Blood.

[90]  P. Kufer,et al.  Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. , 2006, Molecular immunology.

[91]  C. Le,et al.  Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.

[92]  Franco Locatelli,et al.  Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. , 2003, Blood.

[93]  E. Coccia,et al.  Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. , 2002, Blood.

[94]  P. Hoffmann,et al.  Extremely potent, rapid and costimulation‐independent cytotoxic T‐cell response against lymphoma cells catalyzed by a single‐chain bispecific antibody , 2002, International journal of cancer.

[95]  Katia Perruccio,et al.  Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.

[96]  E. Reinherz,et al.  Mechanisms Contributing to T Cell Receptor Signaling and Assembly Revealed by the Solution Structure of an Ectodomain Fragment of the CD3ϵγ Heterodimer , 2001, Cell.

[97]  D. Howard,et al.  The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells , 2000, Leukemia.

[98]  D. McVicar,et al.  Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2. , 2000, Blood.

[99]  J. Klein,et al.  T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation. , 1999, Blood.

[100]  G. Trinchieri,et al.  Interaction of Fc receptor (CD16) ligands induces transcription of interleukin 2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells , 1988, The Journal of experimental medicine.

[101]  J. Bluestone,et al.  Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody , 1985, Nature.

[102]  Osami Kanagawa,et al.  Hybrid antibodies can target sites for attack by T cells , 1985, Nature.

[103]  G. Ossenkoppele,et al.  Impaired antigen presentation in neoplasia: basic mechanisms and implications for acute myeloid leukemia. , 2010, Immunotherapy.

[104]  M. Martelli,et al.  Natural killer cell alloreactivity and haplo-identical hematopoietic transplantation. , 2006, Cytotherapy.

[105]  C. Craddock,et al.  Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. , 2000, Blood.

[106]  M. Horowitz,et al.  Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. , 1993, Blood.

[107]  W. Wilmanns,et al.  Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. , 1990, Blood.